Anti-SMYD5 / SET and MYND domain-containing protein 5

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. SMYD5 antibody detects SET and MYND domain-containing protein 5, a nuclear histone methyltransferase that modulates chromatin structure and transcriptional regulation. Encoded by the SMYD5 gene on chromosome 2q35, this enzyme belongs to the SMYD family of SET domain-containing proteins, which methylate histone lysine residues and regulate gene expression programs involved in differentiation, metabolism, and inflammation. SMYD5 specifically catalyzes methylation of histone H4 on lysine 20 (H4K20) and influences transcriptional repression of inflammatory and developmental genes.Structurally, SMYD5 is a 428-amino-acid protein of approximately 47 kilodaltons containing an N-terminal SET domain responsible for methyltransferase activity, a MYND-type zinc finger that mediates protein-protein interactions, and a C-terminal coiled-coil region that targets chromatin-associated complexes. It localizes primarily to the nucleus and interacts with components of the NCoR and SIN3A transcriptional corepressor complexes, linking histone methylation to large-scale transcriptional silencing.The SMYD5 antibody is widely used in epigenetics, developmental biology, and immunology research to study histone methylation, chromatin regulation, and transcriptional repression. Western blot analysis detects a 47 kilodalton band corresponding to SMYD5, while immunofluorescence shows nuclear punctate staining consistent with chromatin localization. This antibody provides a reliable tool for investigating how methyltransferase activity contributes to transcriptional control and inflammatory gene regulation.Functionally, SMYD5 acts as a negative regulator of inflammation by repressing toll-like receptor (TLR)-inducible genes and maintaining immune tolerance in macrophages. In embryonic development, SMYD5 influences the transcription of genes involved in metabolism and differentiation. Dysregulation of SMYD5 expression has been linked to metabolic disorders, neurodevelopmental abnormalities, and cancer, where altered histone methylation disturbs gene expression balance. The SMYD5 antibody supports mechanistic research into chromatin-based transcriptional regulation and methylation-dependent signaling. NSJ Bioreagents validates this antibody for its applications, ensuring accurate and reproducible results for chromatin biology studies.